Overview
- A peer‑reviewed review published Tuesday, July 14, 2026, in Frontiers in Science proposes expanding use of the glucose ketone index (GKI) as a bedside marker of metabolic state.
- The GKI is a single number derived from a finger‑prick blood test that divides glucose by β‑hydroxybutyrate and was first developed to monitor ketogenic diet adherence in cancer patients.
- Authors argue that a lower GKI—meaning lower blood glucose and higher ketone levels—may signal more efficient mitochondrial ATP production and lower metabolic and inflammatory risk.
- The paper is a synthesis of prior studies rather than new clinical evidence, and the authors call for standardized daily or weekly reporting and large trials to define disease‑specific GKI targets and links to outcomes.
- If trials validate the approach, routine GKI monitoring could help clinicians and patients track responses to diet, fasting, and exercise, but ketogenic strategies are management tools that require medical oversight and attention to social and cultural barriers to adherence.